Archive for the ‘MedicareCard Replacement’ Category

Ten companies manufacturing some of the costliest prescription drugs to participate in first-ever direct negotiations with Medicare. The Biden-Harris Administration announced that all ten drug companies whose drugs were selected for price negotiation with Medicare for the first cycle of the program have decided to participate in those negotiations. These companies manufacture some of the costliest and most commonly used prescription drugs.

These selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20% of total Part D gross covered prescription drug costs between June 1, 2022, and May 31, 2023, which is the period used to determine which drugs were eligible for negotiation. Medicare enrollees taking the ten drugs covered under Part D selected for negotiation paid $3.4 billion in out-of-pocket costs in 2022 for these drugs.

The ten companies participating in the Medicare Drug Price Negotiation Program Drug NameParticipating Manufacturer:

Eliquis/Bristol Myers Squibb
Jardiance/Boehringer Ingelheim
Xarelto/Janssen Pharms
Januvia/Merck Sharp Dohme
Farxiga/AstraZeneca AB
Entresto/Novartis Pharms Corp
Enbrel/Immunex Corporation
Imbruvica/Pharmacyclics LLC
Stelara/Janssen Biotech, Inc.
Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill/Novo Nordisk Inc.

The landmark Inflation Reduction Act allowed Medicare to negotiate prescription drug prices for the first time. In late August, the U.S. Department of Health and Human Services (HHS) announced the ten drugs covered under Medicare Part D selected for the first negotiation cycle. Drug companies that manufacture these drugs have indicated that they will participate in talks with Medicare during the remainder of 2023 and 2024, and any agreed-upon negotiated prices will become effective beginning in 2026.

Over 90 percent of homes had three or more detectable allergens.  Allergens are widespread, but highly variable in U.S. homes, according to the nation’s largest indoor allergen study to date. Researchers from the National Institutes of Health report that over 90 percent of homes had three or more detectable allergens, and 73 percent of homes had at least one allergen at elevated levels. The findings(link is external) were published November 30 in the Journal of Allergy and Clinical Immunology.

Researchers find target to protect hearing during chemotherapy treatment. Scientists have found a new way to explain the hearing loss caused by cisplatin, a powerful drug used to treat many forms of cancer. Using a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear. They also found a region in the inner ear that could be targeted for efforts to prevent hearing loss from cisplatin. The study is published in Nature Communications(link is external), and was supported by the National Institute on Deafness and other Communications Disorders (NIDCD), part of the National Institutes of Health.

Using fruit flies, NIH researchers provide molecular basis for theory of aging.  A shorter life may be the price an organism pays for coping with the natural assaults of daily living, according to researchers at the National Institutes of Health and their colleagues in Japan. The scientists used fruit flies to examine the relationship between lifespan and signaling proteins that defend the body against environmental stressors, such as bacterial infections and cold temperatures. Since flies and mammals share some of the same molecular pathways, the work may demonstrate how the environment affects longevity in humans.

Early and accurate diagnoses of these brain disorders is essential for developing treatments and identifying patients eligible for clinical trials.  National Institutes of Health scientists developing a rapid, practical test for the early diagnosis of prion diseases have modified the assay to offer the possibility of improving early diagnosis of Parkinson’s disease and dementia with Lewy bodies. The group, led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson’s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer’s disease. The test correctly excluded all the 31 controls and diagnosed both Parkinson’s disease and dementia with Lewy bodies with 93 percent accuracy.

New resources from NIH cut the confusion on dietary supplements.

The new year is a time to set new goals, and for many people this means losing weight and improving fitness. Although these goals are best met with a nutritious diet and regular physical activity, many people may turn to dietary supplements for a boost to their routines. To help cut the confusion, the Office of Dietary Supplements (ODS) at the National Institutes of Health has two new resources to help people understand what is known about the effectiveness and safety of many ingredients in dietary supplements promoted for fitness and weight loss.

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease
Effort is part of the Accelerating Medicines Partnership to speed development of disease-altering treatments.

The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Part of the NIH Accelerating Medicines Partnership (AMP), AMP PD will focus on identifying and validating promising markers of disease called biomarkers that may be useful in tracking the progression of PD and could serve as biological targets for the development of new drugs.

Preliminary results suggest strokes also affect the eye.

Research into curious bright spots in the eyes on stroke patients’ brain images could one day alter the way these individuals are assessed and treated. A team of scientists at the National Institutes of Health found that a chemical routinely given to stroke patients undergoing brain scans can leak into their eyes, highlighting those areas and potentially providing insight into their strokes. The study was published in Neurology.

Natural history investigation will deploy latest advances to identify biomarkers, targets for early therapy.

A new clinical study led by the National Eye Institute (NEI), part of the National Institutes of Health, will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). By using the latest technologies to visualize structures within the eye and measure their function, researchers hope to identify biomarkers of disease progression, well before it advances to late-stage disease and causes vision loss. AMD is the leading cause of vision impairment and blindness among people age 50 and older in the United States.

The brain’s internal clock continually takes its temperature

Circuits in the brain act as an internal clock to tell us it is time to sleep and to control how long we then stay asleep. A new study in flies suggests that a part of that clock constantly monitors changes in external temperature and integrates that information into the neural network controlling sleep. The NINDS-supported study was published in Nature.

NIH experts call for transformative research approach to end tuberculosis

A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in the March 2018 issue of The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Robert W. Eisinger, Ph.D., special assistant for scientific projects at NIAID, discuss the need to modernize TB research by applying new diagnostic, therapeutic, and vaccine approaches. The perspective is based on a lecture delivered by Dr. Fauci on Nov. 17, 2017 in Moscow at the first World Health Organization Global Ministerial Conference, “Ending TB in the Sustainable Development Era: A Multisectoral Response.”

Immune cells in the retina can spontaneously regenerate.  NIH discovery in mice could lead to therapies to reduce vision loss from diseases of the retina.

Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). The cells also re-establish their normal organization and function. The findings point to potential therapies for controlling inflammation and slowing progression of rare retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), the most common cause of blindness among Americans 50 and older. A report on the study was published online today in Science Advances. The NEI is part of the National Institutes of Health.

NIH study may help explain why iron can worsen malaria infection
Researchers identify protective role of iron export protein and its mutation.

Researchers at the National Institutes of Health have a possible explanation for why iron can sometimes worsen malaria infection. By studying mice and samples from malaria patients, the researchers found that extra iron interferes with ferroportin, a protein that prevents a toxic buildup of iron in red blood cells and helps protect these cells against malaria infection. They also found that a mutant form of ferroportin that occurs in African populations appears to protect against malaria. These basic findings, published in Science, may help researchers and healthcare officials develop strategies to prevent and treat malaria(link is external) infections, which numbered nearly 216 million worldwide in 2016.

New technique makes heart valve replacement safer for some high-risk patients

Scientists have developed a novel technique that prevents coronary artery obstruction during transcatheter aortic valve replacement (TAVR), a rare but often fatal complication. The method, called Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA), will increase treatment options for high-risk patients who need heart valve procedures. The findings by researchers at the National Institutes of Health will publish in the Journal of the American College of Cardiology: Cardiovascular Interventions on April 2.

NIH completes in-depth genomic analysis of 33 cancer types

Researchers funded by the National Institutes of Health have completed a detailed genomic analysis, known as the PanCancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer.

“This project is the culmination of more than a decade of groundbreaking work,” said NIH Director Francis S. Collins, M.D., Ph.D. “This analysis provides cancer researchers with unprecedented understanding of how, where and why tumors arise in humans, enabling better informed clinical trials and future treatments.”

NIH researchers use genomics to set squamous cell carcinomas apart from other cancers. Results could advance treatments for head and neck and other cancers.

Results could adResearchers supported by the National Institutes of Health have uncovered molecular characteristics that link the genomic profiles of squamous cell carcinomas (SCCs) from five areas of the body and that set these SCCs apart from other cancers. Using a robust dataset of SCCs from the head and neck, lung, esophagus, cervix, and bladder, the researchers also found defining characteristics in subtypes of SCCs associated with tobacco use or human papillomavirus (HPV) infection. This research may lead to more effective diagnosis and treatment of these cancers by helping researchers develop tailored strategies for specific cancer subtypes.vance treatments for head and neck and other cancers.

NIH researchers crack mystery behind rare bone disorder

Researchers at the National Institutes of Health worked with 15 patients from around the world to uncover a genetic basis of “dripping candle wax” bone disease. The rare disorder, known as melorheostosis, causes excess bone formation that resembles dripping candle wax on x-rays. The results, appearing in Nature Communications, offer potential treatment targets for this rare disease, provide important clues about bone development, and may lead to insights about fracture healing and osteoporosis.

Contact Us | Privacy Statement